These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20082481)

  • 1. Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis.
    Montomoli J; Holland-Fischer P; Bianchi G; Grønbaek H; Vilstrup H; Marchesini G; Zoli M
    World J Gastroenterol; 2010 Jan; 16(3):348-53. PubMed ID: 20082481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature.
    Dasarathy J; Alkhouri N; Dasarathy S
    Liver Int; 2011 Oct; 31(9):1250-8. PubMed ID: 21745273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
    Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism.
    Thomsen KL; Sandahl TD; Holland-Fischer P; Jessen N; Frystyk J; Flyvbjerg A; Grønbæk H; Vilstrup H
    Clin Nutr; 2012 Dec; 31(6):940-5. PubMed ID: 22541535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
    Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
    Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Transjugular Intrahepatic Portosystemic Shunt on Nutrition in Liver Cirrhosis Patients: A Systematic Review.
    Gazda J; Di Cola S; Lapenna L; Khan S; Merli M
    Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis.
    Busk TM; Bendtsen F; Poulsen JH; Clemmesen JO; Larsen FS; Goetze JP; Iversen JS; Jensen MT; Møgelvang R; Pedersen EB; Bech JN; Møller S
    Am J Physiol Gastrointest Liver Physiol; 2018 Feb; 314(2):G275-G286. PubMed ID: 29074483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index changes after transjugular intrahepatic portosystemic shunt in individuals with cirrhosis.
    Pang N; Zhao C; Li J; Li L; Yang X; Yang M; Wu Z; Feng D
    Nutrition; 2021 Apr; 84():111095. PubMed ID: 33571910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS).
    Raddatz D; Rossbach C; Buchwald A; Scholz KH; Ramadori G; Nolte W
    Exp Clin Endocrinol Diabetes; 2005 May; 113(5):268-74. PubMed ID: 15926112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
    Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Follow-up study of 116 cases of transjugular intrahepatic portosystemic shunt in the treatment of cirrhotic portal hypertension].
    Liu MH; Zhou F; Wang XB; Chen LP; Li GZ; Zhao Q
    Zhonghua Gan Zang Bing Za Zhi; 2018 Aug; 26(8):596-600. PubMed ID: 30317791
    [No Abstract]   [Full Text] [Related]  

  • 13. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.
    Trevisani F; Merli M; Savelli F; Valeriano V; Zambruni A; Riggio O; Caraceni P; Domenicali M; Bernardi M
    J Hepatol; 2003 Apr; 38(4):461-7. PubMed ID: 12663238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin sensitivity and body composition in cirrhosis: changes after TIPS.
    Holland-Fischer P; Nielsen MF; Vilstrup H; Tønner-Nielsen D; Mengel A; Schmitz O; Grønbaek H
    Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G486-93. PubMed ID: 20489042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
    Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
    Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of transjugular intrahepatic portosystemic stent shunt on systemic cardiocirculatory parameters.
    Saugel B; Mair S; Meidert AS; Phillip V; Messer M; Nennstiel S; Berger H; Gaa J; Wagner JY; Schneider H; Schmid RM; Huber W
    J Crit Care; 2014 Dec; 29(6):1001-5. PubMed ID: 25220530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.